Navigation Links
OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for Second Quarter 2013
Date:8/8/2013

set by lower apatorsen manufacturing costs due to the timing of manufacturing activities.
  • Net loss for the second quarter and six months ended June 30, 2013 was $8.4 million, or $0.57 per diluted common share, and $15.1 million, or $1.03 per diluted common share, respectively. Net loss for the second quarter and six months ended June 30, 2012 was $4.2 million, or $0.29 per diluted common share, and $11.1 million, or $0.89 per diluted common share, respectively. The net loss in the six months ended June 30, 2013 included a non-cash gain on revaluation of the warrant liability of $2.3 million. 
  • The Company had $57.0 million in cash, cash equivalents and short-term investments as of June 30, 2013, compared to $75.4 million as of December 31, 2012.
  • 2013 cash guidance:
  • Net cash requirements are expected to be in the range of $40 - $50 million.
  • Year-end cash, cash equivalents and short-term investments are expected to be in the range of $25 - $35 million.
  • Based on its current expectations, the Company believes its capital resources as of June 30, 2013 will be sufficient to fund its currently planned operations into 2015.
  • At August 8, 2013, The Company had 14,680,395 shares outstanding.
  •  Consolidated Statements of Loss(In thousands, except per share and share data)(unaudited)Three months ended June 30,Six months ended June 30,2013201220132012Collaboration revenue

    $
    ,340$
    2,429$
    ,416$
    3,745Operating expenses:  Research and development

    13,2636,32624,11811,408  General and administrative

    2,4732,0474,9733,784Total operating expenses

    15,7368,37329,09115,192Loss from operations

    (9,396)(5,944)(17,675)(11,447)  Other income (expense)

    9761,7292,558372Net loss

    $
    (8,420)$
    (4,215)$
    (15,117)$
    (11,075)Basic and diluted net loss per share

    $
    (0.57)$
    (0.29)$
    (1.03)$<
    '/>"/>

    SOURCE OncoGenex Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. OncoGenex Announces Multiple Trials in Progress Presentations at the 2013 ASCO Annual Meeting
    2. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013
    3. OncoGenex Pharmaceuticals, Inc. Provides Update on Clinical Development Program and Reports Financial Results for Fourth Quarter and Year End 2012
    4. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
    5. OncoGenex Announces Initiation of the Phase 3 "AFFINITY" Trial for Patients with Advanced Prostate Cancer
    6. OncoGenex Pharmaceuticals, Inc. Reports Second Quarter and First-Half 2012 Financial Results and Reviews Clinical Development Highlights for Custirsen and OGX-427
    7. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity Growth Conference
    8. UPCOMING DEADLINE: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Vanda Pharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of August 24, 2013 to Seek a Lead Plaintiff Position
    9. Imprimis Pharmaceuticals, Inc. to Present at the Southern California Investor Conference on Thursday, August 8, 2013 at the Island Hotel in Newport Beach, CA. The presentation is scheduled to begin at 11 a.m. ET / 8 a.m. PT
    10. OPTIMER PHARMACEUTICALS SHAREHOLDER ALERT: Levi & Korsinsky Investigates Possible Breaches of Fiduciary Duty by Board of Optimer Pharmaceuticals, Inc. in Connection with Sale of Company to Cubist Pharmaceuticals, Inc.
    11. Auxilium Pharmaceuticals, Inc, Announces Second Quarter 2013 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/20/2014)... 20, 2014  BioPontis Alliance for Rare Disease ... announced today the creation of a joint venture ... the rare disease known as Charcot- Marie-Tooth (CMT) ... model earlier this month. Today,s partnership announcement with ... model where researchers and all CMT dedicated organizations ...
    (Date:10/19/2014)... 2014 Große Pharmafirmen werden ... Problem dabei ist, dass große Pharmafirmen nicht willens ... teilen. Es war deshalb nicht einfach, ... umso mehr, dass es uns gelungen ist! Wir ... aufzuschreiben - mit einem Vorbehalt - einige haben ...
    (Date:10/17/2014)... Oct. 17, 2014  Hanger, Inc. (NYSE: ... its results of operations for the quarter ended September ... market closes.  A conference call to discuss these results ... Friday, November 7, 2014. Those wishing to participate should ... November 14, 2014 by dialing 1-855-859-2056 and referencing Conference ...
    Breaking Medicine Technology:The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 2The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 3Vergleichsbericht zu Pharma-Kühlketten und CRT 2
    ... and CEO of Curemark, LLC , ( www.curemark.com ), ... of neurological diseases, moderated the neuroscience roundtable focused on autism ... Hauppauge, New York.   Sponsored by the State ... and Cold Spring Harbor Laboratories, the Life Sciences Summit focused ...
    ... Oct. 11 BioStorage Technologies, a global leader ... storage for the pharmaceutical and biotechnology industries, has ... sample preparation services, including sample aliquoting and nucleic ... need for comprehensive sample management continues to grow, ...
    Cached Medicine Technology:Curemark Moderates Autism Panel at Life Sciences Summit 2010 2Curemark Moderates Autism Panel at Life Sciences Summit 2010 3Industry Leader BioStorage Technologies Broadens Sample Management Operations to Include Laboratory Sample Preparation Services 2
    (Date:10/20/2014)... October 20, 2014 It’s hard to imagine ... orphans and vulnerable children around the world, it’s a reality. ... people, many children are forced to walk barefoot on rocky ... families or play with their friends. , Buckner International's ... Air1 Radio in October to encourage support for ...
    (Date:10/19/2014)... Hastings and Hastings, a Phoenix personal injury ... the greater Phoenix area and across Arizona reports record ... catastrophic automobile accidents. Statistics have indicated a steady increase ... As such, Hastings and Hastings has seen a steady ... who have been injured through no fault of their ...
    (Date:10/19/2014)... 2014 This report provides comprehensive ... complete with comparative analysis at various stages, therapeutics ... route of administration (RoA) and molecule type, along ... releases. It also reviews key players involved in ... features on late-stage and discontinued projects. , Partial ...
    (Date:10/19/2014)... SweetDressy.com, a professional company of women’s dresses ... long evening dresses . All the company’s old ... current discount is up to 66 percent off. ... the fashion field. Its dress specialists are striving to ... parts of the world. All the company’s items are ...
    (Date:10/19/2014)... is a systemic disease that causes inflammation in ... affected members of the ancient Egyptian royal families. ... & Rheumatology , a journal of the American ... instead a degenerative spinal condition called diffuse idiopathic ... the 18th to early 20th Dynasties. , ...
    Breaking Medicine News(10 mins):Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:Promotion For Beautiful Long Evening Dresses Launched By SweetDressy.com 2Health News:Mummy remains refute antiquity of ankylosing spondylitis 2
    ... A new study on old rats by a Penn State ... heart disease and aging in women. , Heart disease is ... of 75. After menopause, women lose their ability to produce ... somehow make women more vulnerable to heart disease and heart ...
    ... The Association of Schools of Public Health, the membership ... in North America, has developed a website with information ... to the H1N1 in communities around the country. ... schools and school spokespeople including instructions how to find ...
    ... insurer reports ... call volume CLEVELAND, May 4 Medical Mutual ... intensifying swine flu outbreak in the United States.In response, the company has posted a message on its ... and member groups to the Centers for Disease Control ...
    ... ( http://www.bullmarket.com ), an online investment ... subscribers with coverage of healthcare-related stocks, including Psych Solutions (Nasdaq: ... Aetna (NYSE: AET ), Covidien (NYSE: ... among others.All paid and trial subscribers to BullMarket.com can now ...
    ... May Help Arthritis Sufferers Manage Inflammation and Stiffness ... American adults currently suffer from arthritis - and as ... May has been deemed National Arthritis Month to ... manage associated symptoms. For many with arthritis, one step ...
    ... Hispanics and African-Americans are at a greater risk , ... to current estimates, more than 1 million cases of ... United States this year. While historically those most at risk ... red hair, light eyes, and generally older populations, dermatologists advise ...
    Cached Medicine News:Health News:Penn State professor investigates estrogen, heart disease connection in women 2Health News:Schools of Public Health Launch Web Portal to Provide Local Media Resources on Response to H1N1 2Health News:Medical Mutual of Ohio Offers Swine Flu Assistance to Customers 2Health News:BullMarket.com Examines Healthcare Stocks: Psych Solutions, Cerner, Aetna, Covidien and HCP 2Health News:Experts Recommend Cherries For Pain Relief From Arthritis 2Health News:Experts Recommend Cherries For Pain Relief From Arthritis 3Health News:Consumer Alert: Dermatologists Warn Skin Cancer is an Equal-Opportunity Health Threat 2Health News:Consumer Alert: Dermatologists Warn Skin Cancer is an Equal-Opportunity Health Threat 3Health News:Consumer Alert: Dermatologists Warn Skin Cancer is an Equal-Opportunity Health Threat 4Health News:Consumer Alert: Dermatologists Warn Skin Cancer is an Equal-Opportunity Health Threat 5
    ... IgM Capture ELISA is for the qualitative ... recombinant antigens (WNRA) in serum as an ... West Nile virus infection in patients with ... must be confirmed by Plaque Reduction Neutralization ...
    ... Used for dilation of urethral ... of the bladder. The flare ... the catheter fits a standard ... is threaded to attach to ...
    Used to dilate the male or female urethra to treat stricture disease. Supplied sterile in peel-open packages. Intended for one-time use....
    The removable inflation adapter allows the ureteroscope to be removed after the catheter is in place. Supplied sterile in peel-open packages. Intended for one-time use....
    Medicine Products: